Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD)
Objective: To establish a large, longitudinal online cohort linked with a selected, intensively assessed cohort of people with and without PD to characterize development and…Botulinum neurotoxin simulation workshop: Impact on resident satisfaction and knowledge
Objective: To assess resident satisfaction and knowledge after a hands-on Botulinum toxin (BoNT) simulation workshop (SW). Background: Despite having an application for BoNT in almost…Impact of Nonmotor Symptoms on The Quality of Life of Parkinson’s Disease Patients
Objective: This study examined the effect of nonmotor symptoms on the quality of life (QoL) of Parkinson's disease (PD) patients. Background: Parkinson's disease has a…Predictors of loss to follow-up three years after inclusion in a prospective longitudinal cohort study in people with early Parkinson’s disease
Objective: To investigate potentially modifiable predictors of loss to follow up (LTFU) three years after inclusion in a nationwide mono-centric Parkinson’s cohort study. Background: LTFU…FACIAL EMOTION EXPRESSIVITY IN PARKINSON’S AND ALZHEIMER’S DISEASES
Objective: We here aimed to comprehensively investigate facial emotion expressivity in Parkinson’s disease (PD) and Alzheimer’s disease (AD) patients compared to healthy controls (HCs). Background:…Nocturnal Polyuria in Parkinson’s Disease
Objective: To characterise the prevalence of nocturnal polyuria in a cohort of people with Parkinson’s disease (PD) with lower urinary tract symptoms. Background: Lower urinary…Distinct Patterns of Tremor Network Microstructure for Essential Tremor and Parkinson’s Disease
Objective: We aimed to identify differential patterns of aberrant tremor network microstructure using DSI among the following groups: (1) ET, (2) PD, and (3) healthy…Improving the design of clinical trials in early-stage Parkinson’s disease by using the estimand framework
Objective: To show how the estimand framework can be used to improve design of clinical trials testing treatments in early-stage Parkinson’s disease (PD). Background: The…PP1α negatively regulates D2 receptor mediated cadmium induced motor dysfunctions: protective potential of Quercetin.
Objective: The present study has been focused to identify the molecular targets that involved in Cadmium-induced motor dysfunctions. At the same time, we also focused…Tracking longitudinal changes in MSA: TALISMAN study protocol
Objective: The European (EU) TALISMAN study will retrospectively and prospectively explore disease progression and the correlation with plasma neurofilament light chain (p-NfL) and brain MRI…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 153
- Next Page »